BioSpace News Archive

Subtle Medical is approved for Phase II of its NIH SBIR grant to develop an innovative artificial intelligence (AI)-powered software, SubtleGAD™, which uses deep learning (DL) to reduce gadolinium dosage needed during MRI exams.

AllStar Health Brands Inc. a specialty pharmaceutical and nutritional supplements company and TPT Global Tech a technology and solutions company are pleased to announce signing a distribution agreement for Mexico and other Latin American countries through TPT Global Tech’s partner New Orbit Technologies.

NMS Labs, one of the nation’s leading forensic science and bioanalytical toxicology laboratories, announced today that Dan T. Monahan is the now President and Chief Executive Officer of the Company

NMS Labs is a leading bioanalytical toxicology and forensic sciences laboratory providing esoteric clinical and forensic services to physicians, attorneys, the criminal justice system, clinical reference labs, pharmaceutical companies, and consumer products manufacturers.

Premier Medical Laboratory Services (PMLS) announces today that they have been named one of the Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook, a leading national healthcare publication.

While many concerned Gulf Coast residents wait for days to receive results from COVID-19 testing, a newly-expanded local lab is processing up to 4,000 rapid tests per day with results in 24-48 hours.

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings call on August 13, 2020 at 4:30 p.m.

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the second quarter ended June 30, 2020. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended June 30, 2020, as well as recent business updates.

Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease